UAC 1117 CAMPATH 1H GIVEN FIVE TIMES WEEKLY IN NON-HODGKINS LYMPHOMA

UAC 1117 CAMPATH 1H 每周给予非霍奇金淋巴瘤五次

• 批准号: 3738992
• 负责人: MANSOOR N SALEH
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3738992
• 关键词: CD antigens; antineoplastics; clinical trials; dosage; drug administration rate /duration; drug adverse effect; human subject; human therapy evaluation; neoplasm /cancer immunotherapy; nonHodgkin's lymphoma

Patients received five times weekly doses starting at 1mg/dose and escalating to 5mg/dose and 25mg/dose. Toxicity consisted of fever, rigors, and increased susceptibility to infections. This study has been closed due to completion of patient accrual. A phase II study is planned at the dose of 25mg/dose administered three times weekly.

患者每周接受5次给药，起始剂量为1 mg/剂， 递增至5 mg/剂和25 mg/剂。 毒性包括发热， 僵硬，增加感染的易感性。 本研究已 由于完成患者招募而关闭。 计划进行II期研究 剂量为25 mg/剂，每周给药三次。